Hormonal
Liraglutide treatment improves beta-cell function (measured by C-peptide and HOMA-B) and reduces the proinsulin-to-insulin ratio compared to placebo when added to metformin and TZD.
If you are taking metformin and a TZD for Type 2 Diabetes, adding liraglutide (1.2 or 1.8 mg once daily) can help your pancreas work better by improving beta-cell function. This is measured by markers like C-peptide and the proinsulin-to-insulin ratio. While this is a technical benefit, it contributes to better overall blood sugar control.
Significant increases in C-peptide and homeostasis model assessment of β-cell function and significant decreases in the proinsulin-to-insulin ratio occurred with liraglutide versus placebo.
Why this rating
Large-scale, double-blind, placebo-controlled, randomized trial.
Source
Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)
Bernard Zinman et al. · Diabetes Care · 2009
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →